Antiplatelet agents are risk factors for cerebellar hemorrhage in patients with primary intracerebral hemorrhage.
Some reports have suggested that the location of primary intracerebral hemorrhage (ICH) is affected by oral antithrombotic agents (ATs). This is important, given the increasing use of ATs to treat arteriosclerotic disease. The aim of this study was to explore whether oral AT therapy increase the incidence of any specific location of primary ICH. A retrospective, single-institution study involving 410 Japanese patients with primary ICH was conducted between July 2003 and June 2009. Bivariate analyses (ie, Fisher's exact 2-tailed test, Student's t test, Welch's test, Wilcoxon's rank-sum test, Pearson's χ(2) test) and multivariate logistic regression analysis were performed for clinical characteristics of these patients. Of the 410 patients, 20% were taking ATs before the onset of primary ICH. The incidence of cerebellar hemorrhage (CH) exceeded that of other types of hemorrhage in patients taking ATs, and the difference was statistically significant on bivariate analysis (P < .0001). On multivariate analysis, only antiplatelet (AP) therapy was found to significantly increase the frequency of CH in patients with primary ICH (P = .0035). Our data indicate that taking APs before the onset of ICH a related factor for CH in Japanese patients with primary ICH.
Matsukawa
Hidetoshi
H
Department of Neurosurgery, St Luke's International Hospital, Chuo-ku, Tokyo, Japan. mahide@luke.or.jp
Shinoda
Masaki
M
Yamamoto
Daisuke
D
Fujii
Motoharu
M
Murakata
Atsushi
A
Ishikawa
Ryoichi
R
Omata
Fumio
F
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000453:epidemiology; D016009:Chi-Square Distribution; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors